Daxocox
enflicoxib
Table of contents
Overview
Daxocox is a veterinary medicine used in dogs to treat pain and inflammation associated with osteoarthritis, a condition causing swelling and pain in the joints. It contains the active substance enflicoxib.
Authorisation details
Product details | |
---|---|
Name |
Daxocox
|
Agency product number |
EMEA/V/C/005354
|
Active substance |
enflicoxib
|
International non-proprietary name (INN) or common name |
enflicoxib
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QM01AH95
|
Publication details | |
---|---|
Marketing-authorisation holder |
Ecuphar NV
|
Date of issue of marketing authorisation valid throughout the European Union |
20/04/2021
|
Contact address |
Legeweg 157-i |
Product information
20/04/2021 Daxocox - EMEA/V/C/005354 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiinflammatory and antirheumatic products
Therapeutic indication
For the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.